By our estimate from its cash flows, the cash it reported covers about 2.2 months of spending at its recent rate. (Company health, computed by us from SEC filings and XBRL, 2026-09-30)
The filing
In the filing's own words, there is “substantial doubt about the Company's ability to conti”. Its previous periodic report, the 10-Q filed Aug 13, 2026, did not match EDGAR full-text search for going-concern language when we last ran it on Nov 14, 2026. The report covers the quarter to Sep 30, 2026 and was filed 43 days after it closed. Since its close of $6.13 on Nov 12, 2026, the day of the filing, the stock has lost 8.6%. (SEC EDGAR, 10-Q, 2026-11-12)
The numbers
Revenue for the three months to Sep 30, 2026 was $1.9M, down from $2.1M in the same quarter a year before, a fall of 7.7%. Its net loss narrowed to $94.9M, from $110.8M a year earlier. Its operations used $79.6M of cash. It ended the quarter with $57.7M in cash, against $65.3M a year earlier, and no debt on its balance sheet. Its current assets of $442.6M compare with current liabilities of $79.4M. Shareholders' equity stood at $378.4M, against $384.8M a year earlier. At its recent quarterly burn of $80.0M, we estimate that cash lasts about 2.2 months. (SEC XBRL company facts, 10-Q, 2026-11-12)
Against its own record
The shares last closed at $5.60 on Nov 13, 2026, 81.5% below their high of the past year, $30.30. That is close to the year's low of $5.52. Over three months the shares are down 77.1%, and over the year up 6.1%. The combined net loss over those four quarters was $423.1M. It has filed 2 prospectus takedowns under its shelf registration in the past year. The Data Desk last wrote about the company on Nov 14, 2026, under the headline “Alumis Inc. flags going-concern doubt in its 10-Q”. (Daily closes (Yahoo Finance chart endpoint), 2026-11-13)
Next to its peers
Its nearest neighbours by market value in pharmaceutical preparations are Ironwood Pharmaceuticals Inc. (IRWD), Ardelyx Inc. (ARDX), Lexicon Pharmaceuticals Inc. (LXRX), Sagimet Biosciences Inc. Series A (SGMT) and Collegium Pharmaceutical Inc. (COLL). Their median one-year return was +24.3%, against +6.1% for ALMS, which leaves it behind the middle of the group. The range runs from Ironwood Pharmaceuticals Inc. (IRWD), at +43.3%, to Ardelyx Inc. (ARDX), at −47.0%. At $727.0M, its market value is the smallest of the group. By the same cash estimate, 1 of those 3 also have less than a year of cash at their recent burn. (MarginsX market map (industries from SEC and the Nasdaq screener), 2026-11-15)
Who else it touches
BlackRock, Inc. reported holding 5.7% of the shares in a Schedule 13G filed Jul 27, 2026. In a Schedule 13D/A filed Jul 2, 2026, AyurMaya Capital Management Company, LP reported 12.3%. In a Schedule 13G filed Apr 7, 2026, Deep Track Capital, LP reported 6.0%. Its officers and directors bought $38.0M and sold $1.5M of stock in the open market over the twelve months through Sep 30, 2026. On the latest quarterly holdings reports that institutional managers file with the SEC, 131 managers held the stock; the largest were BlackRock, Inc., with 8.6 million shares; Vanguard Capital Management LLC, with 4.3 million shares; and State Street Corp, with 2.9 million shares. Over that quarter, 47 of them added to their positions and 35 cut them. (SEC EDGAR, SCHEDULE 13G, 2026-07-27)
What to watch
Its 10-K for the period ending Dec 31, 2026 falls due by Wednesday, March 31, 2027 at the latest, the SEC's deadline of 90 days for non-accelerated filers; larger filers have less time. (SEC, Form 10-K general instructions, 2026-11-15)
By our estimate, the cash on hand at Sep 30, 2026 runs out around Dec 6, 2026 at the recent burn, before the 10-K is due. The 10-K will be the first report to show how far the cash went. (SEC XBRL company facts, 10-Q, 2026-11-12)
Written by the MarginsX Data Desk's template engine from SEC filings and market data, with no AI. Every figure is in the table of facts with its source. For information only. Not investment advice.